PharmaCyte Biotech, Inc. — Director's Dealing 2025

Dec 12, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PharmaCyte Biotech, Inc. (PMCB)
CIK: 0001157075
Period of Report: 2025-04-25

Reporting Person: SCHECHTER JONATHAN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-12	Common Stock	A	150000	—	Acquired	200000	Direct
2025-12-12	Common Stock	F	67500	$1.02	Disposed	132500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-25	Stock Option (Right to Buy)	$1.22	A	63233	Acquired	2035-04-24	Common Stock (63233)	Direct

Footnotes

F1: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

F2: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.